First AD

Second AD

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL 

Video content above is prompted by the following:

How does the prior line of therapy (BTKi vs BCL2i) influence your treatment decision?

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies

Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.